Suppliers and packagers for generic pharmaceutical drug: LACOSAMIDE

LACOSAMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aucta	MOTPOLY XR	lacosamide	CAPSULE, EXTENDED RELEASE;ORAL	216185	NDA	Aucta Pharmaceuticals, Inc.	73289-0063-1	1 BLISTER PACK in 1 CARTON (73289-0063-1) / 14 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK	2023-05-05
Aucta	MOTPOLY XR	lacosamide	CAPSULE, EXTENDED RELEASE;ORAL	216185	NDA	Aucta Pharmaceuticals, Inc.	73289-0063-2	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0063-2)	2023-05-05
Aucta	MOTPOLY XR	lacosamide	CAPSULE, EXTENDED RELEASE;ORAL	216185	NDA	Aucta Pharmaceuticals, Inc.	73289-0064-2	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0064-2)	2023-05-05
Aucta	MOTPOLY XR	lacosamide	CAPSULE, EXTENDED RELEASE;ORAL	216185	NDA	Aucta Pharmaceuticals, Inc.	73289-0065-2	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0065-2)	2023-05-05
Acella	LACOSAMIDE	lacosamide	SOLUTION;INTRAVENOUS	218464	ANDA	Trigen Laboratories, LLC	13811-207-40	10 VIAL, GLASS in 1 CARTON (13811-207-40) / 20 mL in 1 VIAL, GLASS (13811-207-74)	2025-06-30

Lacosamide Drug Substance Suppliers

Last updated: February 19, 2026

This report analyzes key suppliers for the pharmaceutical drug lacosamide, focusing on manufacturing capabilities, regulatory standing, and intellectual property considerations relevant to market entry and supply chain security.

Who are the Primary Manufacturers of Lacosamide Drug Substance?

Several entities manufacture lacosamide drug substance, serving both generic and branded markets. These manufacturers differentiate themselves through scale, technological expertise, and adherence to stringent quality standards.

• UCB Pharma: As the originator of lacosamide (Vimpat®), UCB Pharma maintains significant manufacturing capacity for the active pharmaceutical ingredient (API). Their internal production ensures supply for their branded product and may involve contract manufacturing organizations (CMOs) under their direct oversight. UCB’s manufacturing sites operate under strict Good Manufacturing Practices (GMP) and are subject to regulatory inspections by agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Divi's Laboratories Limited: A prominent Indian API manufacturer, Divi's has established itself as a significant supplier of lacosamide. The company possesses large-scale manufacturing facilities and a strong regulatory track record. Divi's often supplies API to generic drug manufacturers globally. Their facilities are regularly inspected by international regulatory bodies.

• Granules India Limited: Another Indian pharmaceutical company, Granules India is a known producer of lacosamide API. They operate multiple manufacturing sites, adhering to international GMP standards. Granules India supplies API to various markets, including the U.S. and Europe.

• Strides Pharma Science Limited: Strides Pharma Science is involved in the manufacturing of lacosamide API. The company has a global presence with manufacturing facilities designed to meet diverse regulatory requirements.

• Other Generic API Manufacturers: Numerous other API manufacturers, particularly in India and China, are active in the lacosamide market. These include companies that may focus on specific intermediates or the final API, often supplying to smaller generic drug formulation companies. Identifying all such entities requires detailed market intelligence and supply chain mapping.

What are the Key Manufacturing Processes and Technologies for Lacosamide?

The synthesis of lacosamide involves a multi-step chemical process. Key considerations include stereoselectivity, impurity profiling, and efficient scale-up.

• Core Synthesis Route: The primary synthesis of lacosamide typically involves the functionalization of an amino alcohol precursor. A common intermediate is (R)-2-aminopropanamide, which is then reacted with a benzyl halide derivative, such as benzyl bromide or benzyl chloride, in the presence of a base. The critical aspect is controlling the stereochemistry to produce the desired (R)-enantiomer, as the (S)-enantiomer has different pharmacological properties and is considered an impurity.

• Chiral Synthesis/Resolution: To ensure the high enantiomeric purity of lacosamide, manufacturers employ various strategies:

  • Chiral Pool Synthesis: Starting with a chiral precursor that already possesses the desired (R)-configuration.
  • Asymmetric Synthesis: Employing chiral catalysts or auxiliaries to direct the formation of the (R)-enantiomer.
  • Chiral Resolution: Synthesizing a racemic mixture and then separating the enantiomers using chiral chromatography or diastereomeric salt formation.

• Key Reactions and Reagents: Common reactions include amidation, alkylation, and potential chiral separations. Reagents often involve organic solvents, bases (e.g., alkali carbonates, organic amines), and benzylating agents. The choice of reagents and reaction conditions significantly impacts yield, purity, and cost.

• Process Optimization: Manufacturers focus on optimizing reaction conditions to:

  • Maximize yield of the (R)-enantiomer.
  • Minimize formation of impurities, including the (S)-enantiomer and process-related impurities.
  • Reduce cycle times and solvent usage for cost-effectiveness and environmental sustainability.
  • Ensure robust and reproducible processes suitable for large-scale commercial manufacturing.

• Quality Control and Analytical Methods: Rigorous analytical testing is essential throughout the manufacturing process. This includes:

  • High-Performance Liquid Chromatography (HPLC): Used for assay, purity determination, and quantification of related substances, including the (S)-enantiomer. Chiral HPLC is critical for enantiomeric excess (ee) determination.
  • Gas Chromatography (GC): Employed for residual solvent analysis.
  • Mass Spectrometry (MS): Used for structural identification of impurities.
  • Nuclear Magnetic Resonance (NMR) Spectroscopy: For structural confirmation of the API.
  • Karl Fischer Titration: For water content determination.

• Impurity Control: Strict control of impurities is mandated by regulatory authorities. These include:

  • Related Substances: Structurally similar compounds formed during synthesis or degradation.
  • Enantiomeric Purity: The (S)-enantiomer of lacosamide is a critical impurity. Regulatory guidelines typically limit its content to very low levels, often below 0.1%.
  • Residual Solvents: Solvents used in the manufacturing process must be within acceptable limits.
  • Heavy Metals: Contamination with heavy metals must be controlled.

What is the Regulatory Landscape for Lacosamide API?

Regulatory compliance is paramount for API manufacturers, requiring adherence to GMP and successful filings with health authorities.

• Good Manufacturing Practices (GMP): All manufacturers must operate under current GMP standards as defined by agencies like the FDA (21 CFR Parts 210 and 211), EMA, and WHO. This covers facility design, equipment, personnel, production, quality control, and documentation.

• Drug Master Files (DMFs): API manufacturers typically file DMFs (or equivalent dossiers in other regions) with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control procedures, and stability data for the API.

  • U.S. DMF: Submitted to the FDA, allowing drug product manufacturers to reference the API information in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
  • European CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), providing a basis for mutual recognition of quality standards in Europe.
  • Other Regional Filings: Similar dossiers are required for other major markets.

• Regulatory Inspections: API manufacturing sites are subject to routine inspections by regulatory authorities (FDA, EMA, national agencies) to verify GMP compliance. A history of successful inspections is critical for supplier qualification.

• Pharmacopoeial Standards: Lacosamide API must meet specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define tests and acceptance criteria for identity, purity, assay, and other quality attributes.

• ANDA and NDA Filings: Generic drug product manufacturers seeking to market lacosamide formulations must reference approved DMFs for their chosen API suppliers in their ANDA filings. Brand manufacturers reference their own internal API manufacturing data or DMFs in their NDAs.

• Impurity Thresholds: Regulatory agencies set strict limits for impurities. For lacosamide, the (S)-enantiomer is a particularly scrutinized impurity, with typical limits at or below 0.1%.

What are the Intellectual Property Considerations for Lacosamide Suppliers?

The patent landscape for lacosamide dictates market entry for generic manufacturers and influences sourcing strategies.

• Originator Patents: UCB Pharma holds patents covering the lacosamide molecule itself, its therapeutic uses, and manufacturing processes. The primary compound patent for lacosamide expired in many jurisdictions. However, secondary patents may cover specific polymorphic forms, formulations, or novel manufacturing methods.

  • Compound Patent Expiry: The core patent for lacosamide has expired in key markets, paving the way for generic competition. For example, in the U.S., the compound patent typically expired around 2014-2015, subject to patent term extensions.
  • Formulation and Polymorph Patents: UCB may hold patents on specific crystalline forms of lacosamide or advanced drug delivery systems for lacosamide. These can extend market exclusivity for branded products.

• Process Patents: UCB or other entities may hold patents on specific, novel, or improved synthetic routes to lacosamide. Generic API manufacturers must ensure their synthesis routes do not infringe on any valid and unexpired process patents.

  • Freedom to Operate (FTO) Analysis: Generic API suppliers and drug product manufacturers conduct FTO analyses to identify potential patent infringements and design non-infringing processes. This is a critical step before commercialization.

• Generic Entry Timing: The expiry of the compound patent is the primary driver for generic market entry. However, ongoing patent litigation and the existence of secondary patents can delay or impact the launch of generic versions.

• Data Exclusivity: Regulatory data exclusivity periods can also play a role in market access, distinct from patent protection.

• ANDA Litigation: The U.S. Hatch-Waxman Act facilitates generic drug approval but also allows for patent litigation. API suppliers must be prepared for potential legal challenges related to their manufacturing processes or the API itself if it is linked to a patented formulation.

What are the Supply Chain and Business Risks for Lacosamide Sourcing?

Securing a reliable and compliant supply of lacosamide API involves managing various risks.

• Regulatory Compliance Risk:

  • GMP Violations: A single FDA warning letter or import alert for an API supplier can disrupt supply for multiple drug product manufacturers. Auditing and ongoing monitoring of supplier regulatory status are crucial.
  • Inspections Failures: Failure to pass regulatory inspections can lead to a cessation of API supply.

• Quality Risk:

  • Impurity Out-of-Specification (OOS) Results: Discovery of unexpected impurities or deviations from specifications can halt production and necessitate product recalls.
  • Batch-to-Batch Consistency: Ensuring consistent quality across all manufactured batches is essential.

• Geopolitical and Economic Risk:

  • Concentration of Suppliers: Over-reliance on a single country or a small number of manufacturers can create vulnerabilities to geopolitical instability, trade disputes, or localized economic disruptions.
  • Raw Material Shortages: Disruptions in the supply of key starting materials or reagents used in lacosamide synthesis can impact API availability.

• Intellectual Property Risk:

  • Patent Infringement Lawsuits: Generic manufacturers and their API suppliers face risks from patent litigation initiated by originators or other patent holders.
  • FTO Uncertainty: Inaccurate or incomplete FTO analysis can lead to costly legal battles and market exclusion.

• Business Continuity Risk:

  • Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can directly impact manufacturing operations and logistics.
  • Supplier Financial Stability: The financial health of API suppliers should be assessed to mitigate the risk of unexpected business closures.

• Supply Chain Visibility:

  • Lack of Transparency: Insufficient visibility into the entire supply chain, including sub-tier suppliers, can hide potential risks.

Key Takeaways

• UCB Pharma remains a significant producer of lacosamide API for its branded product, while Divi's Laboratories, Granules India, and Strides Pharma Science are key suppliers to the generic market.
• The synthesis of lacosamide requires precise stereochemical control, with enantiomeric purity being a critical quality attribute monitored by chiral HPLC.
• API manufacturers must maintain stringent GMP compliance and file comprehensive DMFs or CEPs with global regulatory authorities.
• The expiry of lacosamide's compound patent has opened the market to generics, but ongoing vigilance regarding process patents and potential litigation is necessary.
• Supply chain risks include regulatory non-compliance, quality deviations, geopolitical factors, and patent infringement.

Frequently Asked Questions

1. What is the typical lead time for securing a new lacosamide API supplier? The lead time can vary significantly, but it typically involves a rigorous qualification process. This includes initial supplier audits, sample analysis, pilot batch production, and final regulatory documentation review, which can range from 6 to 18 months.

2. How is the (S)-enantiomer of lacosamide controlled during manufacturing? Manufacturers control the (S)-enantiomer through optimized synthetic routes that favor the formation of the (R)-enantiomer, employing chiral catalysts or resolutions, and employing sensitive analytical methods like chiral HPLC to detect and quantify any (S)-enantiomer present, ensuring it remains below regulatory limits.

3. Are there specific lacosamide polymorphs that are patented and could impact generic API sourcing? While the primary compound patent has expired, UCB Pharma may hold patents on specific crystalline forms (polymorphs) or solvates of lacosamide. Generic API manufacturers must ensure their manufacturing process results in a polymorph that does not infringe on existing patents or establish freedom to operate concerning polymorphs.

4. What is the impact of FDA warning letters or import alerts on lacosamide API suppliers? An FDA warning letter or import alert can halt the import of API from a non-compliant facility into the United States, severely disrupting supply chains for drug product manufacturers relying on that supplier. It often triggers immediate investigations and potential disqualification of the supplier.

5. What is the typical scale of manufacturing for lacosamide API by major suppliers? Major suppliers like Divi's Laboratories and Granules India operate large-scale API manufacturing facilities capable of producing metric tons of lacosamide API annually to meet global demand for both branded and generic formulations.

Cited Sources

[1] UCB Pharma. (n.d.). Vimpat® (lacosamide) prescribing information. Retrieved from [Manufacturer's Website/Regulatory Agency Database] [2] Divi's Laboratories Limited. (n.d.). Product Portfolio. Retrieved from [Company Website] [3] Granules India Limited. (n.d.). API Products. Retrieved from [Company Website] [4] Strides Pharma Science Limited. (n.d.). API Capabilities. Retrieved from [Company Website] [5] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs — Method for Assessing Systemic Excitatory or CNS Stimulating Effects of New Amino Acids or Derivatives of Amino Acids. (Relevant guidance for impurity assessment, if applicable to stereoisomers). [6] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. [7] United States Pharmacopeial Convention. (n.d.). Lacosamide Monograph. In United States Pharmacopeia. [8] European Pharmacopoeia Commission. (n.d.). Lacosamide Monograph. In European Pharmacopoeia.